Skip to search formSkip to main contentSkip to account menu

The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates

Based on the analyses presented in this series, the final recommended cutpoints for weakness are grip strength <26kg for men and <16kg for women, and for low lean mass, appendicular lean mass adjusted for body mass index <0.789 forMen and women.
View PDF (opens in a new tab)

Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials.

Testosterone replacement in older men was associated with a significantly higher risk of detection of prostate events and of hematocrit >50% than was placebo; he matocrit increase was the most frequent adverse event associated with testosterone replacement.
View on PubMed (opens in a new tab)

Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels.

Transdermal testosterone (5 mg/d) prevented bone loss at the femoral neck, decreased body fat, and increased lean body mass in a group of healthy men over age 65 with low bioavailable testosterone levels, and demonstrated gains in lower extremity muscle strength.
View on PubMed (opens in a new tab)

Cutpoints for Low Appendicular Lean Mass That Identify Older Adults With Clinically Significant Weakness

ALM cutpoints derived from a large, diverse sample of older adults identified lean mass thresholds below which older adults had a higher likelihood of weakness.
View PDF (opens in a new tab)

An Evidence-Based Comparison of Operational Criteria for the Presence of Sarcopenia

The FNIH criteria result in a more conservative operational definition of sarcopenia, and the prevalence was lower compared with other proposed criteria, including the International Working Group and the European Working Group for Sarcopenia in Older Persons.
View PDF (opens in a new tab)

Muscle Quality in Aging: a Multi-Dimensional Approach to Muscle Functioning with Applications for Treatment

A broad, multidimensional perspective of muscle quality in the context of aging and sarcopenia offers comprehensive insights for consideration and integration in developing improved prognostic tools for research and clinical care, while also promoting translational approaches to the design of novel targeted intervention strategies designed to maintain function and mobility into late life.
View on Springer (opens in a new tab)

Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women.

Sarcopenia is common in adults over the age of 65 years and increases with age in women and men and interventions to target nutrition, strength training, and testosterone replacement therapy should be further investigated for their role in preventing muscle loss with age.
View on PubMed (opens in a new tab)

Grip Strength Cutpoints for the Identification of Clinically Relevant Weakness

Cutpoints for weakness derived from this large, diverse sample of older adults may be useful to identify populations who may benefit from interventions to improve muscle strength and function.
View PDF (opens in a new tab)

Creatine supplementation improves muscular performance in older women

Short-term creatine supplementation resulted in an increase in strength, power, and lower-body motor functional performance in older women without any adverse side effects.
View on Springer (opens in a new tab)

Criteria for Clinically Relevant Weakness and Low Lean Mass and Their Longitudinal Association With Incident Mobility Impairment and Mortality: The Foundation for the National Institutes of Health…

Findings support the cut-points for low grip strength and low ALM-to-BMI ratio as candidate criteria for clinically relevant weakness and low lean mass and further validation in other populations and for alternate relevant outcomes is needed.
View PDF (opens in a new tab)
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)